These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20407889)

  • 21. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
    Whitson HE; Lobaugh B; Lyles KW
    Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM
    Nat Clin Pract Rheumatol; 2006 Apr; 2(4):186-7. PubMed ID: 16932682
    [No Abstract]   [Full Text] [Related]  

  • 23. Zoledronic acid for Paget's disease of bone.
    Maricic M
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatotoxicity induced by zoledronic acid in an aged woman with primary osteoporosis.
    Lu Y; Pei Y; Shao Y; Yan S; Ma L; Fang F; Jin M; Liu M; Li J; Li C
    EXCLI J; 2013; 12():115-7. PubMed ID: 27034632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACUTE PHASE REACTIONS AFTER ZOLEDRONIC ACID INFUSION: PROTECTIVE ROLE OF 25-HYDROXYVITAMIN D AND PREVIOUS ORAL BISPHOSPHONATE THERAPY.
    Crotti C; Watts NB; De Santis M; Ceribelli A; Fabbriciani G; Cavaciocchi F; Marasini B; Selmi C; Massarotti M
    Endocr Pract; 2018 May; 24(5):405-410. PubMed ID: 29498910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Bone Scintigraphy Results After Intravenous Zoledronate in Paget's Disease of Bone.
    Reid IR; Maslowski K
    Calcif Tissue Int; 2017 Jul; 101(1):43-49. PubMed ID: 28324123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D
    Bone; 2006 Feb; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone.
    Gennari L; Merlotti D; Mossetti G; Rendina D; De Paola V; Martini G; Nuti R
    Mini Rev Med Chem; 2009 Aug; 9(9):1052-63. PubMed ID: 19689402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of Paget's disease of bone: importance of the zoledronic acid].
    Griz L; Colares V; Bandeira F
    Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):845-51. PubMed ID: 17160207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of zoledronic acid in the management of osteoporosis.
    Maricic M
    Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paget's disease and bisphosphonate-associated osteonecrosis of the jaws.
    Gueiros LA; Lopes MA; Leão JC
    J Oral Maxillofac Surg; 2008 Jun; 66(6):1319. PubMed ID: 18486809
    [No Abstract]   [Full Text] [Related]  

  • 35. Active Paget's disease of bone with normal biomarkers of bone metabolism: a case report and review of the literature.
    Gkouva L; Andrikoula M; Kontogeorgakos V; Papachristou DJ; Tsatsoulis A
    Clin Rheumatol; 2011 Jan; 30(1):139-44. PubMed ID: 20886248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.
    Arden-Cordone M; Siris ES; Lyles KW; Knieriem A; Newton RA; Schaffer V; Zelenakas K
    Calcif Tissue Int; 1997 May; 60(5):415-8. PubMed ID: 9115157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Optimizing therapy in Paget disease].
    Füessl HS
    MMW Fortschr Med; 2005 Dec; 147(51-52):32. PubMed ID: 16402704
    [No Abstract]   [Full Text] [Related]  

  • 38. Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.
    Devogelaer JP; Geusens P; Daci E; Gielen E; Denhaerynck K; Macdonald K; Hermans C; Vancayzeele S; Abraham I; Boonen S
    Calcif Tissue Int; 2014 Mar; 94(3):311-8. PubMed ID: 24271562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Paget's disease of bone: diagnosis and treatment].
    Winter EM; Hamdy NA; de Jongh RT; Eekhoff EM; Zillikens MC; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2016; 160():D254. PubMed ID: 27650015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P; Alvarez L; Vidal S; Martínez MA; Monegal A; Guañabens N
    Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.